Page 38 - HIV/AIDS Guidelines
P. 38

patients with detectable viremia. J Infect Dis. 2006;194(7):926-930.

            6.  Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients
               screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis. 2007;44(4):591-595.

            7.  Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus
               assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother.
               2007;51(2):566-575.
            8.  Trouplin V, Salvatori F, Cappello F, et al. Determination of coreceptor usage of human immunodeficiency virus type 1
               from patient plasma samples by using a recombinant phenotypic assay. J Virol. 2001;75(1):251-259.
            9.  Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1)
               variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a
               pretreatment CXCR4-using virus reservoir. J Virol. 2006;80(10):4909-4920.
            10. Trinh L, Han D, Huang W, et al. Technical validation of an enhanced sensitivity Trofile HIV coreceptor tropism assay for
               selecting patients for therapy with entry inhibitors targeting CCR5. Antivir Ther. 2008;13(Suppl 3):A128
            11. Toma J, Frantzell A, Cook J, et al. Phenotypic determination of HIV-1 coreceptor tropism using cell-associated DNA
               derived from blood samples. Paper presented at: 17th Conference on Retroviruses and Opportunistic Infections;  Feb 16-
               19, 2010, 2010; San Francisco, CA.
            12. Lin NH, Kuritzkes DR. Tropism testing in the clinical management of HIV-1 infection. Curr Opin HIV AIDS.
               2009;4(6):481-487.

            13. Chapman D, Valdez H, Lewis M, et al. Clinical, virologic, and immunologic characteristics of patients with discordant
               phenotypic and genotypic co-receptor tropism test results. Paper presented at: 50th Interscience Conference on
               Antimicrobial Agents and Chemotherapy;  Sep 12-15, 2010, 2010; Boston, MA.
            14. McGovern RA, Thielen A, Mo T, et al. Population-based V3 genotypic tropism assay: a retrospective analysis using
               screening samples from the A4001029 and MOTIVATE studies. AIDS. 2010;24(16):2517-2525.










































            Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents        C-20

                            Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.
   33   34   35   36   37   38   39   40   41   42   43